The FDA approved Rasonque (daraxonrasib) on August 26, 2026 — the first RAS inhibitor in pancreatic cancer. In the first 48 hours, 154 accounts in our curated network posted about the approval, reaching 880,000+ impressions. 118 were physicians.
Dr. Tanios Bekaii-Saab (Mayo Clinic):
"Transformational !!! Decades of hard work — I remember a closing slide on all my pancreas talks over the last 2+ decades about the light at the end of the tunnel - well here we are moving into the light ! Just love it and more to come !!"
Dr. Anirban Maitra (MD Anderson):
"Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer. The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations."
Dr. Wungki Park (MSK) discussed the approval on CNN with Wolf Blitzer on August 27.
Dr. Maitra, on the indication wording:
"The @FDA Daraxonrasib (Rasonque) approval is REALLY broad & the 'OR' in the indication below potentially opens the door for a 'soft 1st line' extension. Also, no requirement to document KRAS status, acknowledging that 95% of #PancreaticCancer harbor a mutation."
Dr. Jun Gong (Cedars-Sinai), to colleagues:
"as the label is written, in a pt fit for multi-agent chemo would you → to daraxonrasib or → w/chemo #1L? Imagine co-pay and drug will be costly w/payor pushback"
Revolution Medicines set the wholesale acquisition cost at $39,800 per 30-day supply (~$478,000/year). STAT's Matthew Herper reported the price to 34,000 impressions.
Dr. Vincent Rajkumar (Mayo Clinic):
"We live in an infinite resources scenario mindset despite finite resources. This type of pricing which is all too common for new cancer drugs is not sustainable."
"how much is too much to ask for? Half a million dollars for a year of therapy is steep. I'm used to thinking of even very expensive new drugs as ~$10k/month, not pricing that starts getting into CAR-T territory... And of course, that's the cost of the drug, not what the individual patient is necessarily paying."
"Daraxonrasib moves undruggable to druggable. But come on. 50 percent dead at just over a year is not exactly wonderful"
Dr. Timothée Olivier posted 10 times in the window — the most posts of any account in the network — around his essay "Daraxonrasib Is FDA-Approved: Both Good News and Bad News," on the efficacy-effectiveness gap and the "not candidates for multiagent systemic therapy" clause.
Most-amplified physician: Dr. Anirban Maitra — 121 accounts retweeted his posts, the most in the network. Other top-amplified accounts: ABC News (83 retweeters), @FDADrugs (79), Mayo Clinic (58), Oncology Brothers (55), Memorial Sloan Kettering (52). Most-mentioned accounts: @RevMedicines (27 mention edges), @FDA (26), @OncoAlert (19), @KRASKickers (13), @PanCAN (11). Largest single audiences: ABC News (49K impressions), Bloomberg (38K), Forbes (28K), Memorial Sloan Kettering (23K), Mayo Clinic (20K).
35-second walkthrough of the launch network. Open the interactive version →
Every node is an account in the launch conversation; node size = impressions, gold ring = verified US physician. Solid orange edges are mentions, dashed blue are retweets. Filter by US physicians, media, or the OncoAlert network — and click any node to open the account on X.
Full RASolute 302 KOL reaction → Watch: the 2-minute KOL video →